Evidence map›Paper›PMID 29740528›Full record

ArticleOsong public health and research perspectives2018

Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C.

Lucas Pereira Jorge de Medeiros, Mario Barreto Correa Lima, Marcia Maria Amêndola Pires, Alessandra Mendonça Almeida Maciel, Renata Barboza Vianna Medeiros, Mariana Dermínio Donadel, Isabela Martins Becattini Pereira, Fábio Marchon Leão, Luiz Eduardo Amorim Correa Lima Pires, Helio Rzetelna and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Osong public health and research perspectives, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lucas Pereira Jorge de MedeirosFederal University of Rio de Janeiro State- UNIRIO, Brazil.
Mario Barreto Correa LimaFederal University of Rio de Janeiro State- UNIRIO, Brazil.
Marcia Maria Amêndola PiresFederal University of Rio de Janeiro State- UNIRIO, Brazil.
Alessandra Mendonça Almeida MacielFederal University of Rio de Janeiro State- UNIRIO, Brazil.
Renata Barboza Vianna MedeirosPontifical Catholic University of Rio de Janeiro - PUC-RJ, Brazil.
Mariana Dermínio DonadelFederal University of Rio de Janeiro State- UNIRIO, Brazil.
Isabela Martins Becattini PereiraFederal University of Rio de Janeiro State- UNIRIO, Brazil.
Fábio Marchon LeãoFederal University of Rio de Janeiro State- UNIRIO, Brazil.
Luiz Eduardo Amorim Correa Lima PiresFaculty of Medicine Souza Marques - FTESM, Brazil.
Helio RzetelnaFaculty of Medicine Souza Marques - FTESM, Brazil.
Carlos Eduardo Brandão-MelloFederal University of Rio de Janeiro State- UNIRIO, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate the impact of 3 treatment regimens upon health-related quality of life and work productivity using patient-reported outcomes (PROs) in chronic hepatitis C infected patients: sofosbuvir (SOF) + daclatasvir (DCV); SOF + DCV + ribavirin (RBV); SOF + simeprevir (SMV).

methods4 questionnaires were used to evaluate PROs before, during and after treatment: Short Form-36 (SF-36), Chronic Liver Disease Questionnaire (CLDQ) - hepatitis C virus (HCV), Work Productivity and Activity Index, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F).

resultsOf the global sample of 55 patients included in this study; SOF + DCV (

conclusionTreatment with SOF + DCV, with or without RBV, results in an improved PRO similar to treatment with SOF + SMV in chronic hepatitis C patients.

Indexed as

antiviral agentshepatitis Cpatient reported outcome measuresquality of life

Identifiers

PMID29740528
PMCPMC5935141

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.